2022 FDA approvals for Novel Drugs (Depopulation Agenda Plan- New Shots to cover Adverse Events from the Abomination Shot)

https://www.nature.com/articles/d41573-023-00001-3

TD Ministries Rumble Videohttps://rumble.com/v25d04d-2022-fda-approvals-for-novel-drugs-depop-agenda-new-shots-to-cover-adverse-.html

Last year the FDA’s Center for Drug Evaluation and Research (CDER) approved 37 novel drugs. This is a drop from the highs of the past 5 years, and brings the rolling 5-year average down to 49 drugs per year. But the 2022 approval number remains above the historic average since 1993, of 34 drugs per year (Figure 1, Table 1).

This document is an alignment to the new drugs and the adverse events from the Pfizer Abomination Shot. The Truth will set you Free!!

Daridorexant (Quviviq)

Idorsia

Orexin receptor antagonist

Insomnia
Abrocitinib (Cibinqo)

Pfizer

JAK inhibitor

Atopic dermatitis
https://pubmed.ncbi.nlm.nih.gov/32509763/
Tebentafusp (Kimmtrak)a

Immunocore

gp100 peptide–HLA×CD3 bispecific T cell engager

Uveal melanoma
OCULAR SARCOIDOSIS – Sarcoidosis is one of the leading causes of inflammatory eye disease. Ocular sarcoidosis can involve any part of the eye and its adnexal tissues, and may cause uveitis, episcleritis/scleritis, eyelid abnormalities, conjunctival granuloma, optic neuropathy, lacrimal gland enlargement and orbital inflammation.
Faricimab (Vabysmo)a

Roche/Genentech

VEGF×ANG2 bispecific antibody

nAMD and DME
Faricimab (Vabysmo)a
Roche/Genentech
VEGF×ANG2 bispecific antibody
nAMD and DME
Faricimab (Vabysmo)a
Roche/Genentech
VEGF×ANG2 bispecific antibody
nAMD and DME

Pfizer Adverse Events Doc- cold agglutinin (1 Finding), Haemolytic anaemia (5 Findings), eosinophilic (3 Findings), neutrophilic (3 Findings), skin disorders (6 Findings)

Sutimlimab (Enjaymo)a

Bioverativ

C1s-targeted mAb

RBC transfusion due to haemolysis in CAD
Sutimlimab (Enjaymo)a

Bioverativ

C1s-targeted mAb

RBC transfusion due to haemolysis in CAD
Mitapivat (Pyrukynd)

Agios

Pyruvate kinase activator

Haemolytic anaemia due to PK deficiency
Mitapivat (Pyrukynd)
Agios
Pyruvate kinase activator
Haemolytic anaemia due to PK deficiency
Pacritinib (Vonjo)

CTI Biopharma

JAK2 inhibitor

Myelofibrosis
Pacritinib (Vonjo)
CTI Biopharma
JAK2 inhibitor
Myelofibrosis
Pacritinib (Vonjo)
CTI Biopharma
JAK2 inhibitor
Myelofibrosis
Pacritinib (Vonjo)
CTI Biopharma
JAK2 inhibitor
Myelofibrosis
Pacritinib (Vonjo)
CTI Biopharma
JAK2 inhibitor
Myelofibrosis
Pacritinib (Vonjo)
CTI Biopharma
JAK2 inhibitor
Myelofibrosis
Ganaxolone (Ztalmy)

Marinus

GABAA receptor positive allosteric modulator

Seizures associated with CDD
Ganaxolone (Ztalmy)
Marinus
GABAA receptor positive allosteric modulator
Seizures associated with CDD
https://www.amjmed.com/article/S0002-9343(17)30986-5/fulltext
Relatlimab; nivolumab (Opdualag)a

Bristol Myers Squibb

LAG3-targeted mAb plus PD1-targeted mAb

Melanoma
Relatlimab; nivolumab (Opdualag)a
Bristol Myers Squibb
LAG3-targeted mAb plus PD1-targeted mAb
Melanoma

Pfizer Adverse Events Doc- Reactive capillary endothelial proliferation (1 Finding), colitis ulcerative (1 Finding), cardiomyopathy (2 Findings), gastritis (5 Findings), diabetes (6 Findings)

https://www.auajournals.org/doi/10.1016/S0022-5347%2801%2964774-8
Lutetium Lu-177 vipivotide tetraxetan (Pluvicto)

Novartis

PSMA-binding radioligand therapeutic agent

PSMA-positive prostate cancer
Oteseconazole (Vivjoa)

Mycovia

Azole antifungal

Vulvovaginal candidiasis
Oteseconazole (Vivjoa)
Mycovia
Azole antifungal
Vulvovaginal candidiasis
Oteseconazole (Vivjoa)
Mycovia
Azole antifungal
Vulvovaginal candidiasis
Mavacamten (Camzyos)
Bristol Myers Squibb
Cardiac myosin inhibitor
Classes of obstructive HCM
Mavacamten (Camzyos)
Bristol Myers Squibb
Cardiac myosin inhibitor
Classes of obstructive HCM
Mavacamten (Camzyos)

Bristol Myers Squibb

Cardiac myosin inhibitor

Classes of obstructive HCM
Vonoprazan; amoxicillin; clarithromycin (Voquezna triple pak)

Phathom

Potassium-competitive acid blocker, plus a penicillin class antibacterial, plus a macrolide antimicrobial

Helicobacter pylori infection


Vonoprazan; amoxicillin; clarithromycin (Voquezna triple pak)
Phathom
Potassium-competitive acid blocker, plus a penicillin class antibacterial, plus a macrolide antimicrobial
Helicobacter pylori infection
Tirzepatide (Mounjaro)
Eli Lilly & Co.
GIP receptor and GLP1 receptor agonist
Type 2 diabetes
Tirzepatide (Mounjaro)

Eli Lilly & Co.

GIP receptor and GLP1 receptor agonist

Type 2 diabetes



Pfizer Adverse Events Doc- psoriasis (2 Findings), amyloidosis (12 Findings), Haemophagocytic
lymphohistiocytosis (1 Finding), facial paralysis (8 Findings)

Tapinarof (Vtama)

Dermavant

Aryl hydrocarbon receptor agonist

Plaque psoriasis

Spesolimab (Spevigo)a

Boehringer Ingelheim

IL-36R-targeted mAb

Generalized pustular psoriasis flares
Tapinarof (Vtama)

Dermavant

Aryl hydrocarbon receptor agonist

Plaque psoriasis

Spesolimab (Spevigo)a

Boehringer Ingelheim

IL-36R-targeted mAb

Generalized pustular psoriasis flares
Vutrisiran (Amvuttra)

Alnylam

TTR-targeted siRNA

Polyneuropathy of hereditary TTR-mediated amyloidosis


Vutrisiran (Amvuttra)
Alnylam
TTR-targeted siRNA
Polyneuropathy of hereditary TTR-mediated amyloidosis


Vutrisiran (Amvuttra)
Alnylam
TTR-targeted siRNA
Polyneuropathy of hereditary TTR-mediated amyloidosis


Olipudase alfa (Xenpozyme)a

Sanofi/Genzyme

Acid sphingomyelinase ERT

Acid sphingomyelinase deficiency


Olipudase alfa (Xenpozyme)a

Sanofi/Genzyme

Acid sphingomyelinase ERT

Acid sphingomyelinase deficiency
Olipudase alfa (Xenpozyme)a
Sanofi/Genzyme
Acid sphingomyelinase ERT
Acid sphingomyelinase deficiency
Olipudase alfa (Xenpozyme)a
Sanofi/Genzyme
Acid sphingomyelinase ERT
Acid sphingomyelinase deficiency
Olipudase alfa (Xenpozyme)a
Sanofi/Genzyme
Acid sphingomyelinase ERT
Acid sphingomyelinase deficiency
Daxibotulinumtoxina (Daxxify)a

Revance

Botulinum toxin

Glabellar lines

Daxibotulinumtoxina (Daxxify)a
Revance
Botulinum toxin
Glabellar lines
Daxibotulinumtoxina (Daxxify)a
Revance
Botulinum toxin
Glabellar lines

Pfizer Adverse Events Doc- psoriasis (2 Findings), blood and lymphatic disorders (1 Finding), hepato (5 Findings), Granul (9 Findings)

Deucravacitinib (Sotyktu)

Bristol Myers Squibb

TYK2 inhibitor

Plaque psoriasis

Deucravacitinib (Sotyktu)
Bristol Myers Squibb
TYK2 inhibitor
Plaque psoriasis
Eflapegrastim (Rolvedon)a

Spectrum

Leukocyte growth factor

Incidence of infection in non-myeloid malignancies, with myelosuppressive drugs
Eflapegrastim (Rolvedon)a
Spectrum
Leukocyte growth factor
Incidence of infection in non-myeloid malignancies, with myelosuppressive drugs
Terlipressin (Terlivaz)

Mallinckrodt

Vasopressin receptor agonist

Kidney function in hepatorenal syndrome
Terlipressin (Terlivaz)
Mallinckrodt
Vasopressin receptor agonist
Kidney function in hepatorenal syndrome


Terlipressin (Terlivaz)
Mallinckrodt
Vasopressin receptor agonist
Kidney function in hepatorenal syndrome
Gadopiclenol (Elucirem)

Guerbet

Gadolinium-based contrast agent

Lesions with abnormal vascularity
Gadopiclenol (Elucirem)
Guerbet
Gadolinium-based contrast agent
Lesions with abnormal vascularity
Gadopiclenol (Elucirem)
Guerbet
Gadolinium-based contrast agent
Lesions with abnormal vascularity

Pfizer Adverse Events Doc- retinitis pigmentosa (1 Finding), sclerosis (16 Findings), hepatic (32 Findings), hepato (5 Findings), myelitis (15 Findings)

Omidenepag isopropyl (Omlonti)
Santen
Prostaglandin E2 receptor agonist
Intraocular pressure in open-angle glaucoma or ocular hypertension


Omidenepag isopropyl (Omlonti)
Santen
Prostaglandin E2 receptor agonist
Intraocular pressure in open-angle glaucoma or ocular hypertension


Omidenepag isopropyl (Omlonti)
Santen
Prostaglandin E2 receptor agonist
Intraocular pressure in open-angle glaucoma or ocular hypertension


Omidenepag isopropyl (Omlonti)
Santen
Prostaglandin E2 receptor agonist
Intraocular pressure in open-angle glaucoma or ocular hypertension
Omidenepag isopropyl (Omlonti)

Santen

Prostaglandin E2 receptor agonist

Intraocular pressure in open-angle glaucoma or ocular hypertension
Sodium phenylbutyrate; taurursodiol (Relyvrio)
Amylyx
Mechanism unknown
Amyotrophic lateral sclerosis
Sodium phenylbutyrate; taurursodiol (Relyvrio)
Amylyx
Mechanism unknown
Amyotrophic lateral sclerosis
Sodium phenylbutyrate; taurursodiol (Relyvrio)
Amylyx
Mechanism unknown
Amyotrophic lateral sclerosis
MARBURG’S VARIANT MULTIPLE SCLEROSIS
Sodium phenylbutyrate; taurursodiol (Relyvrio)

Amylyx

Mechanism unknown

Amyotrophic lateral sclerosis
Futibatinib (Lytgobi)
Taiho Oncology
FGFR kinase inhibitor
FGFR2-aberrant intrahepatic cholangiocarcinoma
Tremelimumab (Imjudo)a
AstraZeneca
CTLA4-targeted mAb
Hepatocellular carcinoma
Futibatinib (Lytgobi)
Taiho Oncology
FGFR kinase inhibitor
FGFR2-aberrant intrahepatic cholangiocarcinoma
Tremelimumab (Imjudo)a
AstraZeneca
CTLA4-targeted mAb
Hepatocellular carcinoma


Futibatinib (Lytgobi)
Taiho Oncology
FGFR kinase inhibitor
FGFR2-aberrant intrahepatic cholangiocarcinoma
Tremelimumab (Imjudo)a
AstraZeneca
CTLA4-targeted mAb
Hepatocellular carcinoma
Futibatinib (Lytgobi)
Taiho Oncology
FGFR kinase inhibitor
FGFR2-aberrant intrahepatic cholangiocarcinoma
Tremelimumab (Imjudo)a
AstraZeneca
CTLA4-targeted mAb
Hepatocellular carcinoma


Futibatinib (Lytgobi)
Taiho Oncology
FGFR kinase inhibitor
FGFR2-aberrant intrahepatic cholangiocarcinoma
Tremelimumab (Imjudo)a
AstraZeneca
CTLA4-targeted mAb
Hepatocellular carcinoma
Futibatinib (Lytgobi)
Taiho Oncology
FGFR kinase inhibitor
FGFR2-aberrant intrahepatic cholangiocarcinoma
Tremelimumab (Imjudo)a
AstraZeneca
CTLA4-targeted mAb
Hepatocellular carcinoma


Futibatinib (Lytgobi)

Taiho Oncology

FGFR kinase inhibitor

FGFR2-aberrant intrahepatic cholangiocarcinoma

Tremelimumab (Imjudo)a

AstraZeneca

CTLA4-targeted mAb

Hepatocellular carcinoma
Futibatinib (Lytgobi)
Taiho Oncology
FGFR kinase inhibitor
FGFR2-aberrant intrahepatic cholangiocarcinoma
Tremelimumab (Imjudo)a
AstraZeneca
CTLA4-targeted mAb
Hepatocellular carcinoma
Teclistamab (Tecvayli)a
J&J
BCMA×CD3 bispecific antibody
Multiple myeloma


Teclistamab (Tecvayli)a
J&J
BCMA×CD3 bispecific antibody
Multiple myeloma


Teclistamab (Tecvayli)a
J&J
BCMA×CD3 bispecific antibody
Multiple myeloma


Teclistamab (Tecvayli)a
J&J
BCMA×CD3 bispecific antibody
Multiple myeloma


Teclistamab (Tecvayli)a
J&J
BCMA×CD3 bispecific antibody
Multiple myeloma


Acute disseminated encephalomyelitis
Teclistamab (Tecvayli)a

J&J

BCMA×CD3 bispecific antibody

Multiple myeloma

Pfizer Adverse Events Doc- ovarian vein thrombosis (1 Finding), diabetes (6 Findings), myel (27 Findings), lung (5 Findings), autoimmune (45 Findings), lymphatic disorders (1 Finding)

Mirvetuximab soravtansine (Elahere)a

Immunogen

FRα-targeted antibody–drug conjugate

Ovarian cancer

Mirvetuximab soravtansine (Elahere)a
Immunogen
FRα-targeted antibody–drug conjugate
Ovarian cancer


Mirvetuximab soravtansine (Elahere)a
Immunogen
FRα-targeted antibody–drug conjugate
Ovarian cancer


Teplizumab (Tzield)a

Provention Bio

CD3-targeted antibody

Delay onset of type 1 diabetes
Teplizumab (Tzield)a
Provention Bio
CD3-targeted antibody
Delay onset of type 1 diabetes
Olutasidenib (Rezlidhia)
Rigel/Forma
IDH1 inhibitor
IDH1-mutated AML


Olutasidenib (Rezlidhia)

Rigel/Forma

IDH1 inhibitor

IDH1-mutated AML

Myeltis Transverse and More with Myel Prefix disease
Olutasidenib (Rezlidhia)
Rigel/Forma
IDH1 inhibitor
IDH1-mutated AML
Adagrasib (Krazati)
Mirati
KRAS-G12C inhibitor
KRASG12C-mutated NSCLC
Adagrasib (Krazati)

Mirati

KRAS-G12C inhibitor

KRASG12C-mutated NSCLC

Autoimmune Lung Disease
Adagrasib (Krazati)
Mirati
KRAS-G12C inhibitor
KRASG12C-mutated NSCLC
Moderna jab patents https://www.modernatx.com/patents open these patents in a browser with a search feature or download and open in an app with a search feature and search things like Hela Cells (Immortal Cancer Cells) Triple Helix, ATCG to ATCCCG (666), Thrombin (Snake Venom), PVA (Quantom Dot),Luciferase, Chimera (MultipleDNA Combos), cDNA (SupremeCourt Ruling to own you), Crispr (DNA Slicing), Prions (Poison),HIV, HEK293 (aborted fetal tissue), programmable nanoparticles, self-assembled… you will find them all in there.
Lenacapavir (Sunlenca)
Gilead
HIV-1 capsid inhibitor
HIV-1 infection
Lenacapavir (Sunlenca)

Gilead

HIV-1 capsid inhibitor

HIV-1 infection

Mosunetuzumab (Lunsumio)a
Roche/Genentech
CD20×CD3 bispecific antibody
Follicular lymphoma
Mosunetuzumab (Lunsumio)a

Roche/Genentech

CD20×CD3 bispecific antibody

Follicular lymphoma

Pfizer Adverse Events Doc- lung (5 Findings), sclerosis (16 Findings), tissue (6 Findings)

Xe 129 hyperpolarized (Xenoview)

Polarean

Hyperpolarized contrast agent

MRI-evaluation of lung ventilation
Xe 129 hyperpolarized (Xenoview)
Polarean
Hyperpolarized contrast agent
MRI-evaluation of lung ventilation
Ublituximab (Briumvi)a
TG Therapeutics
CD20-targeted mAb
Relapsing forms of multiple sclerosis
Multiple Sclerosis Relapse
Ublituximab (Briumvi)a

TG Therapeutics

CD20-targeted mAb

Relapsing forms of multiple sclerosis
Anacaulase (Nexobrid)a
Mediwound
Proteolytic enzymes from pineapple plants
Eschar removal after thermal burns
Anacaulase (Nexobrid)a
Mediwound
Proteolytic enzymes from pineapple plants
Eschar removal after thermal burns
Anacaulase (Nexobrid)a
Mediwound
Proteolytic enzymes from pineapple plants
Eschar removal after thermal burns
Skin and subcutaneous tissue disorders
Anacaulase (Nexobrid)a

Mediwound

Proteolytic enzymes from pineapple plants

Eschar removal after thermal burns

Approvals by the Center for Biologics Evaluation and Research (CBER) — which regulates vaccines, cell and gene therapies, and blood products — bump the number higher, and underline the uptick in gene therapy submissions (Table 2). Two novel products secured Emergency Use Authorizations, an expedited regulatory pathway that rose to prominence during COVID-19 but that is now seeing less use (Table 3).

Pfizer Adverse Events Doc  – Covid-19 (30 Findings), myelitis (15 Findings), measles (1 Finding),

Covid-19 vaccine, mRNA (Spikevax)
Moderna
mRNA vaccine
COVID-19 immunization
Covid-19 Pneumonia
Covid-19 vaccine, mRNA (Spikevax)

Moderna

mRNA vaccine

COVID-19 immunization
Ciltacabtagene autoleucel (Carvykti)

Legend Biotech/J&J

BCMA-targeted genetically modified autologous T cell immunotherapy

Multiple myeloma
Ciltacabtagene autoleucel (Carvykti)
Legend Biotech/J&J
BCMA-targeted genetically modified autologous T cell immunotherapy
Multiple myeloma
Ciltacabtagene autoleucel (Carvykti)
Legend Biotech/J&J
BCMA-targeted genetically modified autologous T cell immunotherapy
Multiple myeloma
Ciltacabtagene autoleucel (Carvykti)
Legend Biotech/J&J
BCMA-targeted genetically modified autologous T cell immunotherapy
Multiple myeloma
Ciltacabtagene autoleucel (Carvykti)
Legend Biotech/J&J
BCMA-targeted genetically modified autologous T cell immunotherapy
Multiple myeloma
Ciltacabtagene autoleucel (Carvykti)
Legend Biotech/J&J
BCMA-targeted genetically modified autologous T cell immunotherapy
Multiple myeloma
Measles, mumps and rubella vaccine live (Priorix)

GSK

Live, attenuated vaccine

Measles, mumps and rubella vaccination
Measles, mumps and rubella vaccine live (Priorix)
GSK
Live, attenuated vaccine
Measles, mumps and rubella vaccination
Measles, mumps and rubella vaccine live (Priorix)
GSK
Live, attenuated vaccine
Measles, mumps and rubella vaccination

Pfizer Adverse Events Doc- Blood (14 Findings), neurological (2 Findings), meningitis (9 Findings), colitis (12 Findings), cystitis (2 Findings)

Betibeglogene autotemcel (Zynteglo)

bluebird bio

β-globin-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy

β-thalassemia
Etranacogene dezaparvovec (Hemgenix)

CSL Behring

Factor IX-encoding adeno-associated virus vector gene therapy

Haemophilia B
Blood and Lymphatic Disorders
Betibeglogene autotemcel (Zynteglo)

bluebird bio

β-globin-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy

β-thalassemia
Etranacogene dezaparvovec (Hemgenix)

CSL Behring

Factor IX-encoding adeno-associated virus vector gene therapy

Haemophilia B
Betibeglogene autotemcel (Zynteglo)

bluebird bio

β-globin-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy

β-thalassemia
Etranacogene dezaparvovec (Hemgenix)

CSL Behring

Factor IX-encoding adeno-associated virus vector gene therapy

Haemophilia B
Elivaldogene autotemcel (Skysona)

bluebird bio

ABCD1-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy

Neurologic dysfunction in CALD
Elivaldogene autotemcel (Skysona)
bluebird bio
ABCD1-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy
Neurologic dysfunction in CALD
Elivaldogene autotemcel (Skysona)
bluebird bio
ABCD1-encoding lentiviral vector for autologous haematopoietic stem cell gene therapy
Neurologic dysfunction in CALD
Fecal microbiota, live (Rebyota)

Rebiotix/Ferring

Fecal microbiota suspension for rectal enema

Recurrence of Clostridioides difficile infection
Fecal microbiota, live (Rebyota)
Rebiotix/Ferring
Fecal microbiota suspension for rectal enema
Recurrence of Clostridioides difficile infection
Fecal microbiota, live (Rebyota)
Rebiotix/Ferring
Fecal microbiota suspension for rectal enema
Recurrence of Clostridioides difficile infection
Fecal microbiota, live (Rebyota)
Rebiotix/Ferring
Fecal microbiota suspension for rectal enema
Recurrence of Clostridioides difficile infection


Nadofaragene firadenovec (Adstiladrin)

Ferring

Interferon α-2b-encoding adenovirus vector gene therapy

BCG-unresponsive non-muscle invasive bladder cancer
Nadofaragene firadenovec (Adstiladrin)
Ferring
Interferon α-2b-encoding adenovirus vector gene therapy
BCG-unresponsive non-muscle invasive bladder cancer


Nadofaragene firadenovec (Adstiladrin)
Ferring
Interferon α-2b-encoding adenovirus vector gene therapy
BCG-unresponsive non-muscle invasive bladder cancer


Nadofaragene firadenovec (Adstiladrin)
Ferring
Interferon α-2b-encoding adenovirus vector gene therapy
BCG-unresponsive non-muscle invasive bladder cancer



Pfizer Adverse Events Doc- Covid-19 (30 Findings) Specifically Covid-19 Pneumonia

Novavax COVID-19 vaccine, adjuvanted

Novavax

Subunit vaccine, adjuvanted

COVID-19 prevention

Bebtelovimaba

Eli Lilly & Co.

Spike-targeted mAb

Mild-to-moderate COVID-19


Novavax COVID-19 vaccine, adjuvanted
Novavax
Subunit vaccine, adjuvanted
COVID-19 prevention
Bebtelovimaba
Eli Lilly & Co.
Spike-targeted mAb
Mild-to-moderate COVID-19

The Depopulation Agenda Plan is commencing..

Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.

#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven  #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus  #Christ 

Leave a Reply

Powered by WordPress.com.

Up ↑

%d bloggers like this: